Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous trastuzumab + pertuzumab value-based time and patient-reported outcomes study
2023-000156-38Phase 4Completed
- Sponsor
- Semmelweis University
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab and pertuzumab in breast cancer (2 arms), sponsored by Semmelweis University. Primary endpoint: Average total turnaround time per patient per visit. Started Feb 2023; status: completed.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-000156-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000156-38.